Navigation Links
Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
Date:7/31/2008

BALTIMORE, July 31 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval for the Company's Abbreviated New Drug Application (ANDA) for Divalproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced.

Lupin's Divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories' Depakote(R) tablets, indicated for the treatment of certain types of seizures and convulsions. It may be prescribed alone or with other epilepsy medications. The delayed-release tablets are also used to control the manic episodes that occur in bipolar disorder. Depakote had annual sales of approximately $803 million for the twelve months ended March 2008, based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs.

The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into New Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.

*Depakote(R) is a registered trademark of Abbott Laboratories.

For More Information:

Contact: Edith St-Hilaire

Director of Marketing

410-576-2000 Ext. 207


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Receives USFDA Approval for Topiramate Tablets
2. Lupin Launches Ramipril Capsules
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
5. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
6. DaVita Receives Civil Complaint
7. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
8. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
9. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
10. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
11. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... ... announced the addition of Victor Giamos, MD to their medical staff, according to ... Partner at North Shore Eye Care, a division of SightMD. Dr. Giamos will ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... ... are well-aware of the following facts at present:, Flu and ... no effect on keeping this particularly bad strain of the flu away , ... sniffling , These facts are well-known among the team at Woodard! About ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon ... , the official journal of The American Society for Aesthetic Plastic Surgery, in ... procedure is designed to correct drooping, retracted lower eyelids, which usually result from ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Wash. , Jan. 16, 2017  Verathon ® Inc., ... announced the launch of new GlideScope ® Spectrum TM ... Dynamic Light Control TM and Ambient Light Reduction TM ... Continue Reading ... ...
(Date:1/16/2017)... When synthetic Fentanyl arrived on the streets in 2015, dealers ... free samples, inviting would-be customers to test a newly-created batch. ... The rapidly-growing demand for the ... morphine, has racked up a staggering death toll across ... recorded fentanyl sales reveals that they have sold nearly 400 ...
(Date:1/16/2017)... Jan. 16, 2017  Northern Colorado,s newest tattoo removal ... laser treatments to Loveland featuring ... on the removal of unwanted tattoos and delivers complete ... cover-ups. "Tattoos are beautiful forms of self-expression, ... hope they would," said Johnny Trzasko , owner. ...
Breaking Medicine Technology: